Mantle Cell Lymphoma | Tumor

Expert Explains Prognosis Indicators, Treatment Plans in MCL

August 4th 2021, 7:00pm

Article

Some patients with mantle cell lymphoma can opt for a wait-and-watch approach, while others will need more aggressive treatment.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021, 1:00pm

Article

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Choosing a BTK Inhibitor for MCL: Consider Side Effects and Insurance Coverage

July 16th 2021, 10:00pm

Article

When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects.

‘No One-Size-Fits-All’ First-Line Treatment for Mantle Cell Lymphoma

July 14th 2021, 6:00pm

Article

Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.

When MCL Relapses Early, Consider Different Treatment Options

July 13th 2021, 11:00pm

Article

Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.

FDA Fast Tracks Drug to Treat MCL

July 2nd 2021, 9:00pm

Article

The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.

MCL Treatment: Differences Exist Between Trial-Based Recommendations and Real-World Care

June 29th 2021, 9:00pm

Article

Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.

Treatment Intensity After Deferring Initial Therapy May Not Indicate Improved Survival in Mantle Cell Lymphoma

May 28th 2021, 1:00pm

Article

Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.

Tecartus May Contribute to Long-Term Responses in Relapsed/Refractory Mantle Cell Lymphoma

May 5th 2021, 1:00pm

Article

Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.

Keep Inspiring

April 28th 2021, 12:30pm

Video

Don’t let your disease define you